

09/113,425

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-59. (cancelled)

60. (currently amended) An ex vivo complex comprising a polypeptide comprising a variant Fc region with increased affinity for an FcγR allotype noncovalently bound to an FcγR allotype or an extracellular domain thereof, wherein said polypeptide comprises an amino acid modification at any one or more of amino acid positions 265, 267, 268, 270, 290, 298, 307, 315, 320, 331, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the FcγR allotype or extracellular domain is bound to a solid phase or to a cell surface.

61. (previously presented) The complex of claim 60 wherein the FcγR allotype for which the polypeptide has increased affinity is selected from the group consisting of FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131 and FcγRIIA-H131.

62. (previously presented) The complex of claim 60 wherein said polypeptide displays increased binding to FcγRIIIA-Phe158.

63. (previously presented) The complex of claim 62 wherein said polypeptide comprises an amino acid modification at any one or more of amino acid positions 290, 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

64.-79. (cancelled)

80. (currently amended) An ex vivo complex comprising a polypeptide comprising a variant Fc region noncovalently bound to an FcγRIIIA-Phe158 allotype or an extracellular domain thereof, wherein said polypeptide comprises an amino acid substitution at any one or more of amino acid positions 290, 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the FcγRIIIA-Phe158 allotype or extracellular domain is bound to a solid phase or

09/713,425

to a cell surface.

81. (previously presented) The complex of claim 80 wherein said polypeptide comprises an antibody.

82. (previously presented) The complex of claim 80 wherein the variant Fc region comprises a variant human IgG Fc region.